基于白消安的预处理方案：并非所有搭档都一样。 - Suppr | 超能文献

Busulfan-based conditioning regimens: not all partners are equal.

作者信息

Giralt Sergio

机构信息

Weill Cornell Medical College, New York, NY, USA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Lancet Oncol. 2015 Nov;16(15):1448-1449. doi: 10.1016/S1470-2045(15)00251-X.

DOI:10.1016/S1470-2045(15)00251-X

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Busulfan-based conditioning regimens: not all partners are equal.基于白消安的预处理方案：并非所有搭档都一样。

Lancet Oncol. 2015 Nov;16(15):1448-1449. doi: 10.1016/S1470-2045(15)00251-X.

2

Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia.老年急性髓系白血病患者需要低毒性的异基因造血细胞移植方案。

Lancet Oncol. 2016 Jan;17(1):e1. doi: 10.1016/S1470-2045(15)00450-7. Epub 2015 Dec 23.

3

Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia--Authors' reply.老年急性髓系白血病患者需要低毒性的异基因造血细胞移植方案——作者回复

Lancet Oncol. 2016 Jan;17(1):e1-2. doi: 10.1016/S1470-2045(15)00586-0. Epub 2015 Dec 23.

4

Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.白消安联合环磷酰胺与白消安联合氟达拉滨作为急性髓系白血病患者异基因造血干细胞移植的预处理方案：一项开放标签、多中心、随机、3 期临床试验。

Lancet Oncol. 2015 Nov;16(15):1525-1536. doi: 10.1016/S1470-2045(15)00200-4. Epub 2015 Sep 28.

5

[A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].白消安联合氟达拉滨与白消安联合环磷酰胺用于急性髓系白血病异基因造血干细胞移植的毒性和疗效比较

Zhonghua Nei Ke Za Zhi. 2012 Nov;51(11):880-4.

6

Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.采用基于 FLAMSA 的大剂量序贯预处理方案对高危骨髓增生异常综合征或继发性急性髓系白血病患者进行 upfront 同种异体造血干细胞移植。

Biol Blood Marrow Transplant. 2012 Mar;18(3):466-72. doi: 10.1016/j.bbmt.2011.09.006. Epub 2011 Sep 29.

7

Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen.白消安与氟达拉滨作为急性髓性白血病异基因移植前预处理疗法的耐受性和疗效：与白消安和环磷酰胺方案的比较

Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):493-500. doi: 10.1016/j.clml.2014.04.006. Epub 2014 Jun 11.

8

Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis.白消安、氟达拉滨和环磷酰胺（BFC）预处理方案使肾上腺脑白质营养不良和黏多糖贮积症患儿在单倍体相合异基因干细胞移植后实现了稳定植入。

Bone Marrow Transplant. 2018 Jun;53(6):770-773. doi: 10.1038/s41409-018-0175-8. Epub 2018 May 3.

9

Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.氟达拉滨与白消安的减低剂量预处理方案对比氟达拉滨与美法仑用于急性髓细胞白血病患者：欧洲血液与骨髓移植组急性白血病工作组的报告

Cancer. 2015 Apr 1;121(7):1048-55. doi: 10.1002/cncr.29163. Epub 2014 Nov 25.

10

[Efficacy of FLAG as initial induction chemotherapy followed by autologous hematopoietic stem cell transplantation after IBu conditioning regimen in acute myeloid leukemia with FLT3 mutations].

Zhonghua Xue Ye Xue Za Zhi. 2014 Jul;35(7):653-5. doi: 10.3760/cma.j.issn.0253-2727.2014.07.019.

引用本文的文献

1

The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience.同种异体干细胞移植在急性髓细胞白血病治疗中的作用：希望与经验的胜利。

Br J Haematol. 2020 Jan;188(1):129-146. doi: 10.1111/bjh.16355. Epub 2019 Dec 10.

2

Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia.异基因造血干细胞移植治疗急性髓系白血病的预处理方案。

Bone Marrow Transplant. 2017 Nov;52(11):1504-1511. doi: 10.1038/bmt.2017.83. Epub 2017 May 15.